HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Steroids Sold As Supplements Targeted In FDA Actions, Congressional Hearing

This article was originally published in The Tan Sheet

Executive Summary

Enhanced FDA enforcement against steroid products sold as dietary supplements is likely reassuring to law-abiding supplement companies

You may also be interested in...



Bodybuilding.com recalls supplements

Bodybuilding.com recalls 65 dietary supplements FDA says are spiked with steroids. The company said in a Nov. 3 release that it is recalling the products due to "an abundance of caution," even though it has not confirmed FDA's concerns or received any adverse event reports for the recalled products. The worldwide recall includes products with the ingredients branded as Superdrol, Madol, Tren, Androstenedine and Turinabol. The recall follows an FDA raid of Bodybuilding.com's facility in Meridian, Idaho, in September (1"The Tan Sheet" Sept. 28, 2009)

Sharfstein Says Spiked Products Top FDA Supplement Enforcement Goals

FDA Principal Deputy Commissioner Josh Sharfstein says that two to-do lists sit on his desk - one of urgent priorities that the agency must address immediately and one of important tasks that can wait

Specter Spares Supplements, Hammers DEA Over Illegal Steroid Products

A Senate Judiciary subcommittee hearing on "hidden steroids" in bodybuilding products sold as supplements took the Drug Enforcement Administration to task for a delay on restricting access to anabolic steroids

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS135614

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel